Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05867017 · ClinicalTrials.gov registry record
Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus
A clinical trial, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- 23
- Enrollment target
NCT05867017 is a clinical trial that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 23 participants.
The verdict
NCT05867017 has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients with COVID-19 and COVID-19 negative individuals on long-term follow up.
Interventions
- OTHER Measure of physiologic parameters
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2025-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05867017
The ClinicalTrials.gov registry entry for NCT05867017 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Measure of physiologic parameters is the first listed.
NCT05867017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05867017 about?
NCT05867017 is a clinical study titled "Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus". Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients with COVID-19 and COVID-19 negative individuals on long-term follow up.
What is the current status of trial NCT05867017?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2023-07-10. Estimated completion is 2025-11-30.
What interventions are being tested in trial NCT05867017?
The interventions under investigation include: Measure of physiologic parameters (OTHER).
Who is sponsoring clinical trial NCT05867017?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.